Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De Stefano, V
Right arrow Articles by Leone, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Stefano, V
Right arrow Articles by Leone, G
Haematologica, Vol 80, Issue 4, 344-356
Copyright © 1995 by Ferrata Storti Foundation

Journal Article

Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia

V De Stefano and G Leone

Divisione di Ematologia, Universita Cattolica, Rome, Italy.

Inherited resistance to activated protein C (APC) was recently recognized as a novel cause underlying venous thrombophilia. In most cases APC-resistance is due to a single point mutation in the factor V gene leading to a replacement of Arg506 with Gln (factor V Leiden). Amino acid substitution occurs at one of the APC cleavage sites of factor Va, rendering it resistant to APC inactivation. Plasma anticoagulant response to exogenous APC as a simple diagnostic assay of APC- resistance shows good sensitivity and specificity as compared to gene analysis, yet standardization of the results needs to be improved. The APC-resistance trait is present in 2%-6% of the general population and was found to be associated with venous thrombophilia in about 20% of patients with unexplained thrombosis. Clinical features are substantially similar to other congenital plasma abnormalities predisposing to thrombosis (antithrombin III, protein C, protein S deficiencies); yet the overall clinical penetrance of the defect seems lower, at least for the heterozygous condition. Preliminary data suggest a higher risk of thrombosis in APC-resistant homozygous individuals or in patients exhibiting APC-resistance together with other thrombophilic genetic defects. To date, genetically determined APC-resistance does not seem to play a significant role in the development of arterial thrombotic disease.


This article has been cited by other articles:


Home page
 CLIN APPL THROMB HEMOSTHome page
A. Majluf-Cruz, M. Moreno-Hernandez, A. Ruiz-de-Chavez-Ochoa, R. Monroy-Garcia, K. Majluf-Cruz, R. Guardado-Mendoza, I. Molina-Avila, I. Isordia-Salas, N. Corona-de la Pena, F. Vargas-Vorackova, et al.
Activated Protein C Resistance and Factor V Leiden in Mexico
Clinical and Applied Thrombosis/Hemostasis, October 1, 2008; 14(4): 428 - 437.
[Abstract] [PDF]

Home page
 PhysiologyHome page
H. Sun
The interaction between pathogens and the host coagulation system.
Physiology, August 1, 2006; 21: 281 - 288.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. A. Kerlin, S. B. Yan, B. H. Isermann, J. T. Brandt, R. Sood, B. R. Basson, D. E. Joyce, H. Weiler, and J.-F. Dhainaut
Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia
Blood, November 1, 2003; 102(9): 3085 - 3092.
[Abstract] [Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
C. Maher, C. Wall, and S. Fanning
Molecular Genetics of Factor V Leiden: Genetic Origins and Modern DNA-Based Detection Strategies
Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 333 - 341.
[Abstract] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 1995 by the Ferrata Storti Foundation.